@article {17039,
	title = {Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients},
	journal = {Bone},
	volume = {13},
	number = {5},
	year = {1992},
	note = {Popovtzer, M M Levi, J Bar-Khayim, Y Shasha, S M Boner, G Bernheim, J Chaimovitz, C Rubinger, D Gafter, U Gazit, D eng Comparative Study 1992/01/01 Bone. 1992;13(5):369-77.},
	pages = {369-77},
	type = {Journal Article},
	abstract = {An increasing body of experimental data suggests a role for 24,25(OH)2D3 in bone metabolism. The present study was carried out to assess a possible therapeutic role of this vitamin D metabolite in renal osteodystrophy. Twenty-two chronic dialysis patients, most of whom were previously maintained on 1 alpha (OH)D3 therapy, received additional treatment with 10 micrograms/day 24,25(OH)2D3 and were compared to 19 patients receiving 1 alpha (OH)D3 alone. Analysis of transiliac bone biopsies obtained at study entry and following 10-16 months of treatment revealed that the combined therapy produced a decrease in bone turnover. Specifically, the addition of 24,25(OH)2D3 inhibited an increase in trabecular bone volume (BV/TV) and suppressed osteoclastic parameters. Thus BV/TV increased from 26.2 +/- 8.6 to 32.1 +/- 7.5\% (p < 0.01) in the 1 alpha (OH)D3 group, but it remained unchanged in the combined therapy group. In contrast, the eroded surface (ES/BS), the osteoclast surface (Oc.S/BS), and the osteoclast numbers were significantly suppressed in patients receiving both 24,25(OH)2D3 and 1 alpha (OH)D3, as compared with those receiving 1 alpha (OH)D3 alone (p < 0.01, p < 0.01, and p < 0.001, respectively). These improvements were independent of changes in 1 alpha (OH)D3 dosage. The extent of bone aluminium deposits was unrelated to the administration of 24,25(OH)2D3 or to its effect. 24,25(OH)2D3 therapy was not associated with any adverse effects.},
	keywords = {24, 25-Dihydroxyvitamin D 3/blood/*therapeutic use Adult Aged Alkaline Phosphatase/blood *Bone Density Calcium/blood Chronic Kidney Disease-Mineral and Bone Disorder/blood/*drug therapy/etiology Creatinine/blood Drug Therapy, Combination Female Humans Hydroxycholecalciferols/blood/*therapeutic use Male Middle Aged Phosphates/blood Renal Dialysis/*adverse effects},
	issn = {8756-3282 (Print) 1873-2763 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1419378},
	author = {Popovtzer, M. M. and Levi, J. and Bar-Khayim, Y. and Shasha, S. M. and Boner, G. and Bernheim, J. and Chaimovitz, C. and Rubinger, D. and Gafter, U. and Gazit, D. and et al.}
}
